



ANNUAL REPORT

AMP

2023

CONTENT

President’s Message	2
AMP Strategic Plan: Mission Statement, Vision Statement, Core Principles.....	3
AMP’s DEI Commitment	4
2023 Board of Directors & Committee Chairs	5
Organizational Relationships.....	6
Advancing Molecular Medicine	7
Innovation & Improved Patient Care	8
Membership & Annual Meeting Overview	9
Education Initiatives	10
Financial Statement	11

President's Message



Dear Colleagues, Patients, and Friends,

In February 2023, Mary Williams informed AMP's Board of Directors of her intention to retire from her position as AMP's Executive Director, effective January 2, 2024. During Mary's 20 years with AMP, including 12 years as its executive director, AMP evolved into the premier molecular diagnostics society we know today. AMP operations have grown more than ten-fold to over \$6.4 million, a staff of 19 full-time employees, and a volunteer roster of over 300 members annually. Membership has grown by over 47% and includes representation from 63 countries, while meeting attendance has increased by 60%. Our community and the patients we serve have also benefitted enormously from her role in *Association for Molecular Pathology v. Myriad Genetics* (2013), the American Civil Liberties Association's Supreme Court legal challenge against gene patents, and in countless other advocacy efforts.

Finding AMP's next executive quickly became a key focus of my term as AMP President. Our Search Committee conducted an extensive national search, fielded 17 applicants, and vetted competitive candidates through three rounds of interviews. By October, the Search Committee and AMP's Board unanimously appointed AMP's very own Director of Strategic Development, Lauren S. Menser, CAE, as the organization's new Chief Executive Officer. Menser has served as Director of Strategic Development at AMP since April 2016, and she has supported AMP in other capacities since 2007. An accomplished senior executive with over 20 years of experience in scientific association leadership, she has a unique and proven track record of relationship building, strategic planning, and championing diversity and professional development at all levels of our society. On behalf of the Board and the Search Committee, I wish to sincerely thank both incredible leaders for their contributions to our society, and we look forward to the AMP achievements yet to come.

AMP is recognized for its unmatched expertise in all aspects of molecular diagnostics. For over 25 years, we've advanced the field through education, clinical practice, and advocacy. I encourage you to take advantage of our broad range of educational offerings, including annual meeting content, webinars and in-depth courses. You may also benefit from reading our freely available practice guidelines in *The Journal of Molecular Diagnostics* (JMD), the highest rated journal in its field. Finally, you can join us at the premier gatherings of molecular professionals – AMP annual meetings and international congresses, which are back in full swing after the challenging early years of the COVID-19 pandemic.

If you're a molecular professional but not yet a member, I encourage you to join us and experience all that AMP has to offer! As a reminder, Associate Membership is free for all qualifying students, residents and fellows for the duration of their training.

Sincerely,

Laura J. Tafe, MD

Dartmouth Hitchcock Medical Center

AMP President and Search Committee Chair, 2023

STRATEGIC PLAN

AMP's strategic plan is dynamic. Implementation success is reviewed and celebrated annually by the Board of Directors, who add and archive strategic goals and objectives as necessary to accommodate the needs associated with this dynamic field. Foundational to its strategic plan are AMP's Mission, Vision, and Core Principles.

MISSION STATEMENT

The Association for Molecular Pathology is a not-for-profit scientific society that advances the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy to enable highest quality health care.

VISION

The Association for Molecular Pathology provides global expertise in molecular testing that drives patient care.

CORE PRINCIPLES

- ▶ Quality Health Care Through Excellence in Clinical Molecular Testing
- ▶ Fostering a Diverse and Inclusive Global Community of Molecular Pathology Professionals
- ▶ Collaboration to Advance Molecular Pathology and Improve Equity in the Delivery of Molecular Laboratory Testing
- ▶ Advocacy that Advances the Field and Practice of Molecular Pathology, Protects Patients, and Improves the Adoption of Innovative Technologies and Tests
- ▶ Innovation to Transform Patient Care

AMP's DEI Commitment

The Association of Molecular Pathology (AMP)'s mission is to enable the highest quality healthcare by advancing the clinical practice, science, and excellence of molecular and genomic laboratory medicine through education, innovation, and advocacy. We believe diversity, equity, and inclusion (DEI) is crucial to our efforts to serve our members and advance clinical care of patients. DEI will help ensure the long-term excellence of both the association and field of molecular and genomic laboratory medicine. At AMP, we define diversity, equity, and inclusion as:

DIVERSITY

Means all the ways that people are unique, which goes beyond gender to include race and ethnicity, sexual orientation, gender identity, age, religion, culture identity, disability, national origin, geographic location, scientific specialty and experience.

EQUITY

Creates fair treatment and access for individuals by establishing policies and processes that both break down existing barriers and prevent the formation of new barriers for the success of members and staff, those they train and mentor, and ultimately the patients whom molecular and genomic laboratory medicine serve.

INCLUSION

Fosters an environment where all members and staff participate fully and are their authentic selves in their local work environment because they feel respected and valued.

Our community consists of healthcare professionals who are committed to helping people. Our field is best served by amplifying diverse voices in our community and including representation from across the spectrum of our community in everything we do. We will work together collaboratively across the healthcare field to address inequities for patients.



2023 Board of Directors & Committee Chairs

President.....	Laura J. Tafe, MD
President-Elect; Awards and Strategic Opportunities Committee Chair.....	Maria E. Arcila, MD
Past President and Nominating Committee Chair.....	Daniel E. Sabath, MD, PhD
Secretary-Treasurer and Finance Committee Chair.....	Alexis B. Carter, MD
Clinical Practice Committee Chair.....	Susan J. Hsiao, MD, PhD
Economic Affairs Committee Chair.....	Samuel K. Caughron, MD
International Affairs Committee.....	Rami Mahfouz, MD, MPH
Membership Affairs Committee Chair.....	Yaolin Zhou, MD
Professional Relations Committee Chair.....	Eric Konnick, MD, MS
Program Committee Chair.....	Yasmine M.N. Akkari, PhD
Publication & Communication Committee Chair.....	Patricia Tsang, MD
Training & Education Committee Chair.....	Alanna Church, MD
Genetics Subdivision Chair.....	Matthew Lebo, PhD
Hematopathology Subdivision Chair.....	Eric Duncavage, MD
Infectious Diseases Subdivision Chair.....	Kirsten St. George, MAppSc, PhD
Informatics Subdivision Chair.....	Annette Leon, PhD, MSc
Solid Tumors Subdivision Chair.....	Anna Yemelyanova, MD
Early Career Member.....	Adam Fisch, MD, PhD
Early Career Member.....	Panieh Terraf, PhD
Patient Advocate.....	Andrea E. Ferris, MBA
Executive Director.....	Mary Steele Williams, MNA, MT(ASCP)SM, CAE



Organizational Relationships

AMP maintains membership in the following organizations:

- ▶ BLOODPAC
- ▶ Cancer Leadership Council (CLC)
- ▶ Federation of American Societies for Experimental Biology (FASEB)
- ▶ Global Alliance for Genomic Medicine
- ▶ Inter-Society Coordinating Committee for Practitioner Education in Genomics (ISCC)
- ▶ Intersociety Pathology Council (IPC)
- ▶ Intersociety Council for Pathology Information (ICPI) – Associate Member
- ▶ Personalized Medicine Coalition (PMC)
- ▶ World Health Organization International Agency for Research on Cancer (IARC)
- ▶ Association for Pathology Informatics (API)

International Affiliates:

- ▶ The Hong Kong Society for Molecular Diagnostic Sciences
- ▶ The Korean Society for Laboratory Medicine
- ▶ The Molecular Pathology Association of India
- ▶ The German Society of Pathology
- ▶ Brazilian Society of Clinical Pathology and Laboratory Medicine
- ▶ The Italian Society of Pathology and Translational Medicine
- ▶ American University of Beirut Medical Center
- ▶ Middle East Molecular Biology Sources

AMP maintains relationships with many professional societies and patient groups. AMP has formal representation in the following groups:

- ▶ Representative to ASCO CancerLinQ Steering Committee
- ▶ Cooperating Society of the American Board of Pathology (ABP)
- ▶ Steering Committee, NIST Genome in A Bottle Consortium
- ▶ Associate Member of the Intersociety Council for Pathology Information (ICPI)
- ▶ Sponsor of the National Academies Roundtable on Genomics and Precision Health
- ▶ Representatives to FNHI Biomarkers Consortium Steering Committees
- ▶ Representative to the College of American Pathology (CAP) Pathology Coding Caucus (PCC)
- ▶ Representative to the CAP Molecular Oncology and Genomic Medicine Resource Committees
- ▶ Food and Drug Administration Network of Experts
- ▶ Representative to FDA Systemic Harmonization and Interoperability Enhancement for Laboratory Data (SHIELD)
- ▶ Representatives to TRUU-Lab initiative

AMP pursued a wide range of economic and policy initiatives in 2023, including:


- › Released/Published 2023 CLIA Modernization Proposal
- › Published Impacts of the European Union IVDR Survey
- › Participated in over 120 meetings on Capitol Hill regarding gene patenting, oversight of laboratory-developed testing procedures, and more
- › Hosted our third Annual Molecular Pathology Economics Summit
- › Published our PAMA Impact Survey
- › Developed new patient-facing resources on molecular testing, breast cancer, infectious diseases
- › Participated in the Clinical Laboratory Fee Schedule Annual Payment Determination Process
- › Engaged CMS on coverage and pricing topics relevant to AMP membership
- › Issued 16 position statements and letters

For a full overview of AMP's Advocacy efforts, please visit our [Position Statements & Letters webpage](#).

Innovation & Improved Patient Care

AMP published six clinical practice guidelines in *The Journal of Molecular Diagnostics* in 2023 and supported numerous efforts to provide member expertise to advance patient care. Over 130 AMP volunteers are also working on more than a dozen guidelines in progress and serving as external representatives on more than 30 projects with other scientific societies and institutions.

- ▶ **Recommendations for Cell-Free Tumor DNA Assay Validations:** A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. December; 25 (12): 876-897
- ▶ **Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites:** A Joint Report of the Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases Society of America, and Pan American Society for Clinical Virology. December; 25 (12): 857-875
- ▶ **CYP3A4 and CYP3A5 Genotyping Recommendations:** A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase. September; 25 (9): 619-629
- ▶ **Recommendations for Next-Generation Sequencing Germline Variant Confirmation:** A Joint Report of the Association for Molecular Pathology and National Society of Genetic Counselors. July; 25 (7): 411-427
- ▶ **Assessments of Somatic Variant Classification Using the Association for Molecular Pathology/American Society of Clinical Oncology/College of American Pathologists Guidelines:** A Report from the Association for Molecular Pathology. February; 25 (2): 69-86
- ▶ **Recommendations for the Use of in Silico Approaches for Next Generation Sequencing Bioinformatic Pipeline Validation:** A Joint Report of the Association for Molecular Pathology, Association for Pathology Informatics, and College of American Pathologists. January; 25 (1): 3-16



THE JOURNAL OF MOLECULAR DIAGNOSTICS

The Official Journal of the Association for Molecular Pathology

Membership and Annual Meeting Overview

2,993
MEMBERS

63
COUNTRIES

Total AMP membership grew for the 17th year in a row in 2023, surpassing **2,993 members** for the first time.

The 2023 Annual Meeting & Expo was held in Salt Lake City, Utah. For our second year of in-person events following the outbreak of COVID-19, we were delighted to see a stronger-than-expected turnout, welcoming 1,933 scientific attendees and 176 exhibiting companies. AMP also celebrated the resumption of international events, hosting the AMP Europe Congress in Milan, Italy.

We sincerely thank our community, exhibitors and corporate sponsors for their ongoing support of AMP events.



1442
Physicians

935
Doctoral Scientists

616
Technologists, Trainees & Other

Education Initiatives

AMP's in-person and digital education initiatives continued to be enhanced in 2023. New this year, our redesigned "Get AMPed!" course held before the annual meeting was offered as morning and afternoon sessions, allowing participants to choose the time slot that best suited their schedule. This enabled a 65% increase in registration over previous in-person Get AMPed! Courses.

In the digital space, AMP hosted its popular the Molecular Genetic Pathology Review live course over four days in May. A total of 79 people, 16 (20%) of whom were from outside of the United States, enrolled in the course. In addition, we attracted over 4,500 active users on our online learning platform, AMPED™ by offering over 398 hours of total recorded content, including 14 new webinars, three courses, 5 new microlearning modules and over 40 hours of recordings from the 2023 AMP Annual Meeting.

To learn more, visit educate.amp.org.

There have been **more than 2,000** user visits to the MIMP card homepage in the past 6 months.

AMP **partnered with three educational providers** and presented at three organizations to create new resources and educate other healthcare professionals on molecular pathology.

AMP Education is expanding their educational offering for Medical Technologists with two flashcards: **(1) Technologist in Molecular Biology: Laboratory Operations** and **(2) Technologist in Molecular Biology: Molecular Techniques**.

There were **over 31,000 active users** who visited AMPED™ from April 2023 – December 2023, resulting in close to **280,000 page views**.

STRATEGIC INITIATIVE REVENUE OVER EXPENSES

	2023	2022	2021
Advocacy	\$ (736,955)	\$ (184,444)	\$ (505,376)
Communications & Outreach	\$ (193,014)	\$ (202,822)	\$ (179,004)
Education	\$ 1,712,267	\$ 1,793,395	\$ 248,073
Innovation & Improved Patient Care	\$ (560,820)	\$ (129,286)	\$ (182,833)
Membership & Management Services	\$ (324,519)	\$ (227,834)	\$ 296,469

EXCESS REVENUE OVER EXPENSES	\$ (103,042)	\$ 1,049,009	\$ (322,671)
---	---------------------	---------------------	---------------------



ASSOCIATION
FOR MOLECULAR
PATHOLOGY

**6120 Executive Boulevard
Suite 700
Rockville, Maryland, 20852**

amp.org